Jenna Andrews
Research
Publications
2024
Mtb-Selective 5‑Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities
Boshoff H, Young K, Ahn Y, Yadav V, Crowley B, Yang L, Su J, Oh S, Arora K, Andrews J, Manikkam M, Sutphin M, Smith A, Weiner D, Piazza M, Fleegle J, Gomez F, Dayao E, Prideaux B, Zimmerman M, Kaya F, Sarathy J, Tan V, Via L, Tschirret-Guth R, Lenaerts A, Robertson G, Dartois V, Olsen D, Barry C. Mtb-Selective 5‑Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities. ACS Infectious Diseases 2024, 10: 1679-1695. PMID: 38581700, DOI: 10.1021/acsinfecdis.4c00025.Peer-Reviewed Original ResearchConceptsLinezolid-resistant mutantsDrug-resistant patientsAntitubercular activityN-acetyl metaboliteOxazolidinone prodrugMechanism of actionC3HeB/FeJ miceAntimycobacterial activityN-acetyl transferaseSusceptible to inhibitionCross-resistanceOxazolidinoneCompoundsMoleculesMammalian metabolismN-acetyltransferaseProdrugToxicityMoietyProtein synthesisLinezolidC3HeB/FeJCaseumPatientsLiving cells
2021
Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis
Xie Y, de Jager V, Chen R, Dodd L, Paripati P, Via L, Follmann D, Wang J, Lumbard K, Lahouar S, Malherbe S, Andrews J, Yu X, Goldfeder L, Cai Y, Arora K, Loxton A, Vanker N, Duvenhage M, Winter J, Song T, Walzl G, Diacon A, Barry C. Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis. Science Translational Medicine 2021, 13 PMID: 33536283, PMCID: PMC11135015, DOI: 10.1126/scitranslmed.abd7618.Peer-Reviewed Original ResearchConceptsPET/CT imagingPET/CTDrug treatmentCT imagingDrug combinationsD-glucose positron emission tomographyRecent phase 3 clinical trialsPhase 3 clinical trialsEarly bactericidal activity studyDrug combination activitySputum bacterial loadFirst-line chemotherapyPhase 3 trialHigh FDG uptakeLung lesion volumeActivity of pyrazinamideNew TB drugsPositron emission tomographyExperimental drug treatmentDrug regimensRadiological responseClinical outcomesFDG uptakeLung lesionsTB drugs
2020
Digital Image Analysis of Heterogeneous Tuberculosis Pulmonary Pathology in Non-Clinical Animal Models using Deep Convolutional Neural Networks
Asay B, Edwards B, Andrews J, Ramey M, Richard J, Podell B, Gutiérrez J, Frank C, Magunda F, Robertson G, Lyons M, Ben-Hur A, Lenaerts A. Digital Image Analysis of Heterogeneous Tuberculosis Pulmonary Pathology in Non-Clinical Animal Models using Deep Convolutional Neural Networks. Scientific Reports 2020, 10: 6047. PMID: 32269234, PMCID: PMC7142129, DOI: 10.1038/s41598-020-62960-6.Peer-Reviewed Original ResearchConceptsConvolutional neural networkNeural networkDeep convolutional neural networkHistopathological image analysisPulmonary pathologyTesting of novel therapiesAnimal modelsSemi-quantitative histopathology scoresImage recognitionUser limitationsNon-clinical animal modelsHistopathological imagesSeverity of diseaseTreatment of tuberculosisSoftware toolsTreatment cohortsNovel therapiesPulmonary tissueDisease progressionHistopathological analysisMouse modelPreclinical evaluationHistopathological scoresSuccessful treatmentPathological features
2019
Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development
Beites T, O’Brien K, Tiwari D, Engelhart C, Walters S, Andrews J, Yang H, Sutphen M, Weiner D, Dayao E, Zimmerman M, Prideaux B, Desai P, Masquelin T, Via L, Dartois V, Boshoff H, Barry C, Ehrt S, Schnappinger D. Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development. Nature Communications 2019, 10: 4970. PMID: 31672993, PMCID: PMC6823465, DOI: 10.1038/s41467-019-12956-2.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PhysiologicalAnimalsAntitubercular AgentsCallithrixDrug DevelopmentElectron TransportElectron Transport Complex IIIElectron Transport Complex IVGene Knockdown TechniquesImidazolesIn Vitro TechniquesLungMiceMycobacterium tuberculosisNADH DehydrogenasePiperidinesPyridinesTuberculosisTuberculosis, PulmonaryConceptsTuberculosis drug developmentDrug developmentTreatment of MtbDisease progressionMost lesionsOxidase inhibitorsClinical useType-2 NADH dehydrogenaseMycobacterium tuberculosisMiceRespiratory chainFatty acidsIntrinsic plasticityRespiratory enzymesInflammationClofazimineStandard growth mediumLesionsTuberculosis
2016
Magnetic-adhesive based valves for microfluidic devices used in low-resource settings
Harper J, Andrews J, Ben C, Hunt A, Murton J, Carson B, Bachand G, Lovchik J, Arndt W, Finley M, Edwards T. Magnetic-adhesive based valves for microfluidic devices used in low-resource settings. Lab On A Chip 2016, 16: 4142-4151. PMID: 27713988, DOI: 10.1039/c6lc00858e.Peer-Reviewed Original ResearchConceptsDevelopment of lab-on-a-chip systemsMicrofluidic devicesLab-on-a-chip systemsMicro total analytical systemControlling microfluidic flowValve actuationLab-on-a-chip platformsControl fluid flowValve conceptMicrofluidic flowPower requirementsFluid flowHand-held magnetOn-demand transportLow costOuter surfaceDisk magnetsDevicesExternal magnetReagent storageDesignOn-device